Vancouver, BC & Tokyo & Waltham, Mass. – SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; “Modalis”), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting …
Vancouver, British Columbia and Columbus, Ohio, May 6, 2025 — SOLVE FSHD, a venture philanthropy organization committed to accelerating therapies for facioscapulohumeral muscular dystrophy (FSHD), today announced a $3 million investment in Armatus Bio, a biotechnology company developing next-generation vectorized RNAi therapeutics for neuromuscular diseases. The investment will support ARM-201, Armatus Bio’s AAV-delivered microRNA therapy …
Vancouver, BC, March 25, 2025 – SOLVE FSHD, a venture philanthropic organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), is pleased to announce a strategic collaboration with Transcripta Bio, a cutting-edge AI-driven drug discovery company. This collaboration will focus on leveraging Transcripta Bio’s advanced drug screening platform to identify and develop promising therapeutic candidates …
Company to present at J.P. Morgan Healthcare Conference on Tuesday, Jan 13, 2026 SAN FRANCISCO–(BUSINESS WIRE)–Epicrispr, a clinical-stage company pioneering gene-modulating therapies, today reported early clinical data from its ongoing first-in-human, open-label study evaluating EPI-321, an investigational epigenetic therapy for facioscapulohumeral muscular dystrophy (FSHD). Epicrispr holds the first and only open epigenetic editing Investigational New …
− First patient with facioscapulohumeral muscular dystrophy (FSHD) dosed with Restem-L umbilical lining modified progenitor cells (UMPCs) − The Phase 1/2a study will evaluate the safety and preliminary efficacy of Restem-L in patients with FSHD − Clinical study is funded by SOLVE FSHD MIAMI and VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) — RESTEM …
Altay Therapeutics is pleased to announce that the FDA has granted Orphan Drug Designation to DX5057, the first and only oral small molecule DUX4 inhibitor in development for facioscapulohumeral muscular dystrophy (FSHD). FSHD affects ~40,000 people in the U.S. and leads to progressive muscle weakness, disability and loss of independence, yet no therapies are currently …